The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Open accessAbstract
BACKGROUND: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS: -mutated cancer. Secondary end points included overall response and safety. RESULTS: -mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. CONCLUSIONS: -mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the use of which as a single-agent is now suboptimal in the second line”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperglycemia occurs early during therapy (median time of onset of about 2 weeks from initiation of alpelisib) with an incidence of $60% overall and typically resolves upon treatment cessation (220-222).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence interval (CI) 0.50-0.85, P < 0.001].”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Toxicity was substantially increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead to dose reductions/interruptions in around 70% of patients and discontinuations in 25%.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046
Self-citationUS Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194
Self-citationO’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Self-citationRugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationMiller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538
Self-citationFritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 2018 December 13 (Epub ahead of print).30543347
- Juric D Ciruelos E Rubovszky G et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4–8 2018. abstract.
Cited by
Sorted by citations
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., Falco, V. D., Upadhyay, A., Kandimalla, R. J. L., Chaudhary, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 2,011
Loibl, S., Poortmans, P. M., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,791
Self-citationBreast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D. M., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C. T., ELIAS, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,602
Self-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R. A., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,523
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“The SOLAR-1 phase III, randomised, placebo-controlled trial evaluated the role of alpelisib, an oral inhibitor of the phosphoinositide 3-kinase alpha (PI3Ka) isoform, in combination with fulvestrant, for postmenopausal women andmenwhohad previously been treated with an AI.(58) In the PIK3CA-mutated cohort, alpelisib p…”
MethodInfluentialSelf-citationLiquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,235
Self-citationKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L., Huang, L., Liu, C., Shao, Z., & Yu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 1,170
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W., Poortmans, P., Regan, M. M., Senn, H.-J., Winer, E. P., Gnant, M. I., Aebi, S. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 875
Self-citationCapivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Self-citationPI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 810
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 792
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Burstein, H. J., Curigliano, G., Loibl, S., Dubsky, P. C., Gnant, M., Poortmans, P. M., Colleoni, M. A., Denkert, C., Piccart, M. J., Regan, M. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz235 · Cited by 689
Self-citationPan-cancer image-based detection of clinically actionable genetic alterations
Kather, J. N., Heij, L. R., Grabsch, H. I., Loeffler, C. M. L., Echle, A., Muti, H. S., Krause, J., Niehues, J., Sommer, K. A. J., Bankhead, P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0087-6 · Cited by 686
Harnessing multimodal data integration to advance precision oncology
Boehm, K. M., Khosravi, P., Vanguri, R., Gao, J., & Shah, S. P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00408-3 · Cited by 662
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Self-citationCirculating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 555
Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., Clark, T., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0237802 · Cited by 516
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 553
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 494
Self-citationSpring, L. M., Wander, S. A., André, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 488
Self-citation2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 453
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Self-citationBreast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · 癌症：英文版 · doi:10.1002/cac2.12358 · Cited by 453
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez‐Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M. J., González‐Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó‐Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 402
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 404
Milbury, C. A., Creeden, J., Yip, W., Smith, D. L., Pattani, V. P., Maxwell, K., Sawchyn, B., Gjoerup, O. V., Meng, W., Skoletsky, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264138 · Cited by 399
Turner, N. C., Kingston, B., Kilburn, L., Kernaghan, S., Wardley, A. M., Macpherson, I. R., Baird, R. D., Roylance, R. R., Stephens, P., Oikonomidou, O., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30444-7 · Cited by 376
Fasting-mimicking diet and hormone therapy induce breast cancer regression
Caffa, I., Spagnolo, V., Vernieri, C., Valdemarin, F., Becherini, P., Wei, M., Brandhorst, S., Zucal, C., Driehuis, E., Ferrando, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2502-7 · Cited by 366
Rugo, H. S., Lerebours, F., Ciruelos, E. M., Drullinsky, P. R., Ruíz‐Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00034-6 · Cited by 349
Self-citationGupta, G. K., Collier, A. L., Lee, D. C., Hoefer, R. A., Zheleva, V. P., van Reesema, L. L. S., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 336
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Self-citationVernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319
Burstein, H. J., Somerfield, M. R., Barton, D. L., Dorris, A., Fallowfield, L. J., Jain, D., Johnston, S. R. D., Korde, L. A., Litton, J. K., Macrae, E. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01392 · Cited by 336
Self-citationSignaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Mosele, F., Stefanovska, B., Lusque, A., Dien, A. T., Garberis, I., Droin, N. M., Tourneau, C. L., Sablin, M., Lacroix, L., Enrico, D. H., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.006 · Cited by 316
Self-citationctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 311
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
Turner, N. C., Im, S., Saura, C., Juric, D., Loibl, S., Kalinsky, K. M., Schmid, P., Loi, S., Sunpaweravong, P., Musolino, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404625 · Cited by 325
Self-citationInsulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0329-9 · Cited by 288
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H. M., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 299
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A. N., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 296
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Stejskal, P., Goodarzi, H., Srovnal, J., Hajdúch, M., Veer, L. V. ‘., & Magbanua, M. J. M. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01710-w · Cited by 317
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 290
Self-citationPersonalized Medicine: Recent Progress in Cancer Therapy
Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. M. R. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 301
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 294
Alpelisib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01161-6 · Cited by 280
Painter, C., Jain, E., Tomson, B. N., Dunphy, M., Stoddard, R. E., Thomas, B. S., Damon, A. L., Shah, S., Kim, D., Zañudo, J. G. T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0749-z · Cited by 293
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T. G., Healy, C., Peterson, R., Yanase, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0830 · Cited by 276
Self-citationPI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
Marquard, F. E., & Jücker, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113729 · Cited by 271
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Bartolomucci, A., de Nóbrega, M., Ferrier, S. T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 301
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar, J. S., Gast, K. C., Quiroga, D. M., Lustberg, M. B., & Williams, N. O. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840984 · Cited by 261
Gallagher, E. J., & LeRoith, D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0295-5 · Cited by 241
Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies
Mäkinen, T., Boon, L. M., Vikkula, M., & Alitalo, K. K. (2021) · Circulation Research · doi:10.1161/circresaha.121.318142 · Cited by 237
Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.013 · Cited by 238
Self-citationWaarts, M. R., Stonestrom, A. J., Park, Y. C., & Levine, R. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154943 · Cited by 249
Jones, R. H., Casbard, A. C., Carucci, M., Cox, C., Butler, R., Alchami, F., Madden, T., Bale, C. J., Bezecny, P., Joffe, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30817-4 · Cited by 242
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Li, H., Prever, L., Hirsch, E., & Gulluni, F. (2021) · Cancers · doi:10.3390/cancers13143517 · Cited by 233
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Fluorine-containing drugs approved by the FDA in 2019
Mei, H., Remete, A. M., Zou, Y., Moriwaki, H., Fustero, S., Kiss, L., Soloshonok, V. A., & Han, J. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.050 · Cited by 230
Circulating tumor DNA: current challenges for clinical utility
Dang, D. K., & Park, B. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154941 · Cited by 239
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
Grabuschnig, S., Bronkhorst, A. J., Holdenrieder, S., Rodriguez, I. R., Schliep, K. P., Schwendenwein, D., Ungerer, V., & Sensen, C. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218062 · Cited by 237
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
The present and future of PI3K inhibitors for cancer therapy
Castel, P., Toska, E., Engelman, J. A., & Scaltriti, M. (2021) · Nature Cancer · doi:10.1038/s43018-021-00218-4 · Cited by 229
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
Nunnery, S. E., & Mayer, I. A. (2020) · Drugs · doi:10.1007/s40265-020-01394-w · Cited by 225
Self-citationBreast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238
Rayadurgam, J., Sana, S., Mayarambakam, S., & Gu, Q. (2020) · Organic Chemistry Frontiers · doi:10.1039/d0qo01146k · Cited by 216
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 224
Bai, J., Qiu, S.-Q., & Zhang, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01366-y · Cited by 221
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
Nair, A. S., Singh, A. K., Kumar, A., Kumar, S., Sunitha, S., Koyiparambath, V. P., Pappachen, L. K., Rangarajan, T. M., Kim, H., & Mathew, B. (2022) · Processes · doi:10.3390/pr10102054 · Cited by 207
Novel roles of phosphoinositides in signaling, lipid transport, and disease
Hammond, G. R. V., & Burke, J. E. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.12.007 · Cited by 203
Clinical utility of circulating tumor cells: an update
Vasseur, A., Kiavué, N., Bidard, F., Pierga, J., & Cabel, L. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12869 · Cited by 204
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Leiphrakpam, P., & Are, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063178 · Cited by 193
Rugo, H. S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S. M., Jurado, J. C., Juric, D., Mayer, I., Ciruelos, E. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.001 · Cited by 193
Self-citationCirculating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 201
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Zhu, K., Wu, Y. Q., He, P., Fan, Y. J., Zhong, X., Zheng, H. Y., & Luo, T. L. (2022) · Cells · doi:10.3390/cells11162508 · Cited by 197
Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jérusalem, G., Bachelot, T., Laurentiis, M. D., Thomas, G., Placido, P. D., Arpino, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30420-6 · Cited by 190
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
The Lancet Breast Cancer Commission
Coles, C. E., Earl, H. M., Anderson, B. O., Barrios, C. H., Bienz, M., Bliss, J. M., Cameron, D., Cardoso, F., Cui, W., Francis, P. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00747-5 · Cited by 209
Self-citationTherapeutic resistance to anti-oestrogen therapy in breast cancer
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 182
Aftimos, P. G., Oliveira, M., Irrthum, A., Fumagalli, D., Sotiriou, C. P., Gal‐Yam, E. N., Robson, M. E., Ndozeng, J., Leo, A. D., Ciruelos, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1647 · Cited by 180
Self-citationHuppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
Self-citationVepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Campone, M., Laurentiis, M. D., Jhaveri, K. L., Hu, X., Ladoire, S., Patsouris, A., Zamagni, C., Cui, J., Cazzaniga, M. E., Çil, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505725 · Cited by 193
Self-citationNiu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
New and Emerging Targeted Therapies for Advanced Breast Cancer
Lau, K., Tan, A. M., & Shi, Y. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042288 · Cited by 171
Metadata
- Authors
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D.
- Affiliations
- Université Paris-Sud (FR)
- From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l’Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) — all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt — both in Germany (S.L.); UCSF Helen Diller Family Comprehensive...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-16
- Volume
- 380
- Issue
- 20
- Pages
- 1929-1940
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945564879
- Cited by
- 2,622
- References
- 25
- Citations by year
- 2026: 314 · 2025: 356 · 2024: 370 · 2023: 329 · 2022: 375 · 2021: 450 · 2020: 345 · 2019: 81
- FWCI
- 231.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- alpelisib, PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, PI3Kα inhibitor, fulvestrant, endocrine therapy, hyperglycemia, diarrhea, adverse events
- MeSH terms
- Fulvestrant, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Female, Humans, Middle Aged, Mutation, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
